Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Saccharomyces boulardii inhibits NF-kappa B-mediated IL-8 gene expression

S. boulardii produces a soluble anti-inflammatory factor which may mediate beneficial effects in intestinal disease, report researchers at in a late-breaking abstract to the American Gastroenterological Association.

News image

fiogf49gjkf04

The probiotic yeast, Saccharomyces boulardii ameliorates intestinal injury and inflammation caused by a variety of bacterial and viral pathogens.

In this study, researchers from the United States hypothesized that S. boulardii acts by modulating the host's intestinal inflammatory response.

Dr Stavros Sougioultzis's team aimed to identify specific mechanisms for the beneficial effects of S. boulardii. They examined the yeast's ability to influence host cell signaling and pro-inflammatory gene expression.

The active component in S. boulardii is a small (≤1 kD), heat stable, water soluble molecule.
American Gastroenterological Association

The team stimulated HT-29 human colonocytes and THP-1 human monocytes with interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, ToxA (Clostridium difficile Toxin A) or lipopolysaccharide (LPS). This was performed in the presence or absence of S. boulardii culture supernatant (SbS).

They measured the production of the pro-inflammatory chemokine IL-8 in the condition media by Enzyme-Linked Immunosorbent Assay.

The researchers also evaluated IL-8 mRNA levels by RT-PCR.

They measured the effect of SbS on I-kappa B alpha degradation using Western blotting, and on NF-kappa B-DNA binding using Electrophoretic Mobility Shift Assay (EMSA).

In addition, NF-kappa B-regulated gene expression was evaluated by transient transfection of THP-1 cells with an NF-kappa B-responsive luciferase reporter gene.

The researchers found that SbS inhibited IL-8 protein production in IL-1 beta stimulated HT-29 cells by 75% TNF alpha stimulated HT-29 cells by 85%, and ToxA stimulated HT-29 cells by 90% (<0.001 for each). It also prevented upregulation of IL-8 mRNA, as determined by RT-PCR.

The team observed a similar inhibitory effect in IL-1 beta or LPS-stimulated THP-1 cells.

Furthermore, SbS also prevented I kappa B alpha degradation, NF-kappa B - DNA binding and NF-kappa B-reporter gene up-regulation following THP-1 cell activation.

The research team also performed purification and characterization studies. These included cesium chloride density gradient ultra-centrifugation, gel filtration, and matrix assisted laser desorption time of flight mass spectroscopic examination. This analysis indicated that the active component in SbS is a small (≤1 kD), heat stable, water soluble molecule.

The team concluded that S. boulardii produced a soluble factor that inhibits NF-kappa B activation and NF-kappa B-mediated IL-8 gene expression in cytokine-, ToxA- or LPS-stimulated intestinal epithelial cells and monocytes.

They think that this anti-inflammatory factor may mediate S. boulardii's beneficial effects in intestinal disease.

AGA
20 May 2003

Go to top of page Email this page Email this page to a colleague

 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Worldwide H.pylori prevalence
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation
 20 March 2018 
Bloody vs coffee-grounds hematemesis
 20 March 2018 
Acute lower GI bleeding in the UK
 20 March 2018 
Therapeutic strategies for IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us